Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Karen O. Klein"'
Publikováno v:
Frontiers in Pediatrics, Vol 12 (2024)
Background and aim of the studyWe previously published the increased frequency of new CPP cases during the Covid-19 pandemic in our pediatric endocrinology clinic at Rady Children's Hospital in San Diego, CA, US. We conducted this follow-up study to
Externí odkaz:
https://doaj.org/article/fb8d72a6505248db8cf2b2446f2dea37
Publikováno v:
Frontiers in Pediatrics, Vol 10 (2022)
Background and aim of the studyThe frequency of new visits for precocious puberty increased during the Covid-19 pandemic in the pediatric endocrinology clinic at Rady Children's Hospital in San Diego, CA, US. A few recent studies have shown an increa
Externí odkaz:
https://doaj.org/article/6c22c3a063b1419e8a3548bd63f603fa
Autor:
Jadranka Popovic, Mitchell E. Geffner, Alan D. Rogol, Lawrence A. Silverman, Paul B. Kaplowitz, Nelly Mauras, Philip Zeitler, Erica A. Eugster, Karen O. Klein
Publikováno v:
Frontiers in Pediatrics, Vol 10 (2022)
Gonadotropin-releasing hormone agonists (GnRHa's) are the standard treatment for children with central precocious puberty (CPP). We aim to present data on available GnRHa options with an easy-to-review table and discuss factors that influence treatme
Externí odkaz:
https://doaj.org/article/5a6c026d6afd496abf8abf6dc6199d95
Publikováno v:
Journal of Pediatric Endocrinology and Metabolism. 35:1401-1409
Objectives To study total growth, rate of bone maturation, and menarche after discontinuation of Gonadotropin releasing hormone agonist (GnRHa) treatment for central precocious puberty (CPP). Methods Twenty girls with CPP on treatment with GnRHa were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9caae59b4010cbddd9baf1a53464512b
https://doi.org/10.1515/jpem-2022-0389
https://doi.org/10.1515/jpem-2022-0389
Autor:
Marcela Vargas Trujillo, Peter A. Lee, Kent Reifschneider, Philippe F. Backeljauw, Sanja Dragnic, Stephen Van Komen, Jun Yu, Karen O. Klein
Publikováno v:
Journal of pediatric endocrinologymetabolism : JPEMReferences.
Objectives It is important to understand what variables influence change in predicted adult height (PAH) throughout GnRHa treatment for central precocious puberty (CPP) to individualize treatment decisions and optimize care. Methods Changes in PAH, c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f572662254bd6379903706cc621417c7
https://pubmed.ncbi.nlm.nih.gov/36473097
https://pubmed.ncbi.nlm.nih.gov/36473097
Publikováno v:
Journal of Pediatric Endocrinology and Metabolism. 34:733-739
Objectives Gonadotropin-releasing hormone agonist treatment is important for optimal growth in girls with central precocious puberty (CPP). Data are lacking regarding benefit to height outcome when treatment is started after chronological age (CA) of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f9622baa520a1cbc6f73e66a035c7cc
https://doi.org/10.1515/jpem-2021-0114
https://doi.org/10.1515/jpem-2021-0114
Publikováno v:
Journal of the Endocrine Society. 6:A607-A608
Introduction Clinical signs of puberty, growth rate, rate of bone maturation, luteinizing hormone concentrations and estimates of change in predicted adult height are the common variables for assessing efficacy of central precocious puberty (CPP) the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6979da372fd607ddf234412f8e5fb70e
https://doi.org/10.1210/jendso/bvac150.1261
https://doi.org/10.1210/jendso/bvac150.1261
Autor:
Karen O Klein, Susan A. Phillips
Publikováno v:
Journal of Pediatric and Adolescent Gynecology. 32:460-468
Girls with either hypo- or hypergonadotropic hypogonadism need treatment with estrogens to initiate puberty and maintain a normal hormonal milieu. The focus of this review is hormone replacement treatment in girls with hypogonadism, to initiate and p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1c39254636218327e239139f2c7bc67
https://doi.org/10.1016/j.jpag.2019.04.010
https://doi.org/10.1016/j.jpag.2019.04.010
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 25:836-846
Central precocious puberty (CPP), early onset of puberty caused by the premature activation of the hypothalamic-pituitary-gonadal axis, is a rare disease affecting children of both sexes. There is limited evidence that quantifies the economic burden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a2b1a67e048bcd84ba4b0fb47394b1c
https://doi.org/10.18553/jmcp.2019.25.7.836
https://doi.org/10.18553/jmcp.2019.25.7.836
Autor:
Mirta Gryngarten, Erica A. Eugster, Karen O Klein, Bradley S. Miller, Matthew Benson, Gad B. Kletter, Nelly Mauras, Tala Dajani, Analia Freire
Publikováno v:
The Journal of Clinical Endocrinology and Metabolism
Context Gonadotropin-releasing hormone agonists (GnRHas) are standard of care for central precocious puberty (CPP). A 6-month subcutaneous injection has recently been approved by the Food and Drug Administration. Objective Determine efficacy, pharmac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9c58b51f658d1daee9f34c94f61091b
http://europepmc.org/articles/PMC7442270
http://europepmc.org/articles/PMC7442270